Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

642.25 -9.55 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Regeneron (REGN) Q2 EPS Jumps 53%
Via The Motley Fool
Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday?
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close. 
Via Benzinga
Why Regeneron (REGN) Stock Is Trading Up Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst... 
Via StockStory
Topics Artificial Intelligence
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. 
Via Benzinga
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q2 2025 Earnings Estimates but Faces Muted Market Reaction
Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B. 
Via Chartmill
Topics Earnings
Regeneron’s (NASDAQ:REGN) Q2: Strong Sales
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was... 
Via StockStory
Regeneron Reports Second Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Exploring Regeneron Pharmaceuticals's Earnings Expectations
 
Via Benzinga
Earnings Scheduled For August 1, 2025
 
Via Benzinga
Regeneron (REGN) Q2 Earnings: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Wall Street might be underestimating these companies' potential. 
Via The Motley Fool
Topics Stocks
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Low-Volatility Stocks We Steer Clear Of
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Regeneron Pharmaceuticals?
 
Via Benzinga
1 Healthcare Stock on Our Buy List and 2 to Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts
 
Via Benzinga
1 Cash-Heavy Stock to Own for Decades and 2 to Ignore
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy
A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws. 
Via Stocktwits
Topics Bankruptcy
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
2 Beaten-Down Stocks to Buy and Hold
Via The Motley Fool
Topics Death
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.